Multinationals trade price for volume
Eli Lilly has reduced Mounjaro prices across several presentations used in type 2 diabetes treatment. According to local pharmacy quotes collected by FurtherBrazil, some Mounjaro starter packs (2.5 mg and 5 mg) are now being offered around R$2,250 (roughly US$410), down from roughly R$3,300 (roughly US$600) earlier in the year. Higher-dose presentations are also being offered at lower prices in pharmacy channels, with patient-support discounts bringing them materially below earlier list levels.
The timing is strategic. Brazil has seen a rapid expansion of GLP-1 and related incretin therapies, driven by demand for both diabetes and obesity treatment. At the same time, the market now includes manipulated formulations and parallel channels that sit alongside branded products. Eli Lilly holds the patent on tirzepatide, Mounjaro’s active ingredient. However, Brazilian law allows compounding pharmacies to prepare medicines for individual patients with a medical prescription. What was once a niche activity has scaled up. According to reports in Brazilian media citing import data for tirzepatide active pharmaceutical ingredient, inputs sufficient for tens of millions of compounded doses entered the country over a recent six-month period.
This shift is reshaping incentives. A larger, price-sensitive patient base is emerging, but the economics for originator brands are changing. The Mounjaro price cut suggests Lilly is prepared to trade some margin for share and volume in a market that could be one of the biggest GLP-1 franchises outside the United States. It also reflects rising pressure from a parallel market that can undercut list prices and shift prescribing decisions, especially where payers or patients bear high out-of-pocket costs.
Regulators are responding. Brazil’s health regulator Anvisa has signalled plans to intensify oversight of compounded tirzepatide, aiming to curb industrial-scale operations that go beyond the concept of one-to-one magistral preparation. Stronger enforcement could reduce some pressure on branded drugs. However, it also introduces execution and compliance risks for both pharmacies and suppliers, and investors will need to track how quickly new rules translate into action on the ground.
Domestic semaglutide reshapes the price curve
While tirzepatide faces competition from compounded rivals, semaglutide is moving into a post-patent phase. With key semaglutide patents beginning to expire in several major markets and Brazilian authorities clearing at least one locally produced semaglutide therapy, domestic producers are starting to enter the segment, which is beginning to alter the cost curve for GLP-1 therapy in Brazil. EMS has obtained Anvisa approval for a locally produced semaglutide injection and is positioning it with aggressive pricing.
One domestic semaglutide pen is being marketed at a price reportedly around half that of imported brands, with treatment-plan discounts further reducing average monthly costs for patients. The company is highlighting a lower-cost treatment plan to attract prescribers and patients across both full treatment courses and individual pen purchases.
Eurofarma has signalled plans to enter semaglutide-based therapies, with local press reporting that it aims to compete on price with imported brands. That places domestic products well below the historical pricing of imported brands and adds a third competitive axis alongside originator GLP-1s and compounded formulations. As more local manufacturers enter, the reference price for GLP-1 treatment in Brazil is likely to track these lower levels rather than the earlier high-end benchmark.
For multinational drug makers, this combination of parallel markets, patent expiries and assertive domestic players compresses the room for premium pricing. For Brazilian generics and branded generics companies, the opportunity is significant but not without risk. They stand to capture rising volumes in obesity and diabetes care, yet face potential future regulatory tightening, evolving clinical guidelines and heightened scrutiny of manufacturing quality and pharmacovigilance.
For investors, the Mounjaro price cut and the arrival of cheaper domestic semaglutide pens signal a pivot from a pure pricing story to a volume-driven, highly competitive market. The next phase will hinge on Anvisa’s enforcement stance, the speed of payer and prescriber adoption of local products, and how aggressively global firms adjust their pricing and access strategies in Brazil’s GLP-1 arena.
